AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+11.4%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$254M
AUM Growth
+$254M
(-2.4%)
Cap. Flow
-$24.8M
Cap. Flow
% of AUM
-9.74%
Top 10 Holdings %
Top 10 Hldgs %
51.68%
Holding
90
New
19
Increased
14
Reduced
15
Closed
19
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$12M |
| 2 |
Biogen
BIIB
|
$11.4M |
| 3 |
Prothena Corp
PRTA
|
$6.83M |
| 4 |
Establishment Labs
ESTA
|
$6.75M |
| 5 |
Kura Oncology
KURA
|
$5.85M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$25.2M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$16.1M |
| 3 |
Merck
MRK
|
$12.8M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$6.35M |
| 5 |
Ventyx Biosciences
VTYX
|
$5.23M |
Sector Composition
| 1 | Healthcare | 94.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $21.4M | 7.46% | 92,500 -500 | -0.5% | -$116K |
|
|
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $17.5M | 6.11% | 550,000 +170,000 | +45% | +$5.4M |
|
|
3
Establishment Labs
ESTA
$1.2B
| $14.5M | 5.07% | 211,608 +98,384 | +87% | +$6.75M |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $12.3M | 4.31% | 321,017 -655,004 | -67% | -$25.2M |
|
|
5
Teva Pharmaceuticals
TEVA
$21.1B
| $12M | 4.21% | +1,600,000 | New | +$12M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $11.6M | 4.04% | 201,887 +66,024 | +49% | +$3.79M |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $11.5M | 4.02% | 1,050,118 -33,000 | -3% | -$361K |
|
|
8
Biogen
BIIB
$19.4B
| $11.4M | 3.98% | +40,000 | New | +$11.4M |
|
|
9
Kura Oncology
KURA
$686M
| $9.63M | 3.36% | 910,317 +553,030 | +155% | +$5.85M |
|
|
VRNA
10
Verona Pharma
VRNA
$9.16B
| $9.46M | 3.31% | 447,667 -5,154 | -1% | -$109K |
|
11
Arcellx
ACLX
$3.85B
| $7.15M | 2.5% | 226,275 +23,441 | +12% | +$741K |
|
|
12
Prothena Corp
PRTA
$441M
| $6.83M | 2.38% | +100,000 | New | +$6.83M |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $5.58M | 1.95% | 900,723 +216,596 | +32% | +$1.34M |
|
14
Astria Therapeutics
ATXS
$349M
| $5.42M | 1.89% | 650,875 +121,506 | +23% | +$1.01M |
|
15
Ascendis Pharma
ASND
$11.8B
| $5.16M | 1.8% | 57,760 +17,760 | +44% | +$1.59M |
|
16
Immunovant
IMVT
$2.56B
| $4.93M | 1.72% | +260,000 | New | +$4.93M |
|
17
Viking Therapeutics
VKTX
$3.04B
| $4.86M | 1.7% | 300,000 -322,249 | -52% | -$5.22M |
|
18
AstraZeneca
AZN
$248B
| $4.29M | 1.5% | 60,000 | – | – |
|
|
INZY
19
DELISTED
Inozyme Pharma
INZY
| $4.19M | 1.46% | 751,796 | – | – |
|
20
Cytokinetics
CYTK
$4.23B
| $4.08M | 1.43% | 125,148 -96,315 | -43% | -$3.14M |
|
|
AUTL
21
Autolus Therapeutics
AUTL
$399M
| $3.78M | 1.32% | +1,589,017 | New | +$3.78M |
|
22
Immatics
IMTX
$619M
| $3.46M | 1.21% | +300,000 | New | +$3.46M |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| $3.41M | 1.19% | +130,000 | New | +$3.41M |
|
|
24
Ventyx Biosciences
VTYX
$171M
| $3.3M | 1.15% | 100,696 -159,312 | -61% | -$5.23M |
|
|
RETA
25
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.97M | 1.04% | +29,105 | New | +$2.97M |
|